Journal
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
Volume 53, Issue 27, Pages 6938-6941Publisher
WILEY-V C H VERLAG GMBH
DOI: 10.1002/anie.201400533
Keywords
cancer therapy; photodynamic therapy; platinum; porphyrinoids; red light
Categories
Funding
- Forschungskredit of the University of Zurich
- PD Vereinigung of the University of Zurich
- Swiss National Science Foundation [PP00P2_133568]
- University of Zurich
- Stiftung fur Wissenschaftliche Forschung of the University of Zurich
- Novartis Jubilee Foundation
- Swiss National Science Foundation (SNF) [PP00P2_133568] Funding Source: Swiss National Science Foundation (SNF)
Ask authors/readers for more resources
Despite the extensive use of porphyrins in photodynamic therapy (PDT), tetraplatinated porphyrins have so far not been studied for their anticancer properties. Herein, we report the synthesis of such novel platinum-porphyrin conjugates as well as their photophysical characterization and in vitro light-induced anticancer properties. These conjugates showed only minor cytotoxicity in the dark, but IC50 values down to 19 nm upon irradiation with light at 420 nm. These values correspond to an excellent phototoxic index (PI=IC50 in the dark/IC50 in light), which reached 5000 in a cisplatin-resistant cell line. After incubation with HeLa cells, nuclear Pt concentrations were 30 times higher than with cisplatin. All of these favorable characteristics imply that tetraplatinated porphyrin complexes are worthy of exploration as novel PDT anticancer agents in vivo.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available